NANO-PARTICLES THAT CONTAIN SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE AS ADJUVANTS IN VACCINES

This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the hum...

Full description

Saved in:
Bibliographic Details
Main Authors MESA PARDILLO, Circe, LÓPEZ LÓPEZ, Miguel Antonio, SÁNCHEZ RAMÍREZ, Belinda, TOLÓN MURGUÍA, Blanca Idelmis, JUNCO BARRANCO, Jesús Arturo, VEREZ BENCOMO, Vicente Guillermo, CRUZ RODRÍGUEZ, Mabel, FERNÁNDEZ MOLINA, Luis Enrique, PÉREZ MARTÍNEZ, Dayana, HERNÁNDEZ FERNÁNDEZ, Diana Rosa, FERNÁNDEZ GÓMEZ, Audry, BERGADO BÁEZ, Gretchen, MANSO VARGAS, Ángel Alexis, CHAO GARCÍA, Lisset, GONZÁLEZ SUÁREZ, Narjara
Format Patent
LanguageEnglish
Published 25.05.2022
Online AccessGet full text

Cover

More Information
Summary:This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) ofNeisseria meningitidisin solutions containing fully synthetic variants of the GM3 ganglioside.
Bibliography:Application Number: ZA20200003218